ERBB2 and neoplasm: For a neoadjuvant training cohort, HER2DX variables were associated with pCR (i.e., immune, proliferation, and HER2 amplicon) and non-pCR (i.e., luminal and tumor and nodal staging), with continuous HER2DX pCR likelihood score significantly associated with pCR (P < 0.0001).